Journal of International Oncology ›› 2017, Vol. 44 ›› Issue (8): 633-637.doi: 10.3760/cma.j.issn.1673-422X.2017.08.020

Previous Articles     Next Articles

Immunotherapy for lymphoma

Wang Jiangtao, Guan Tao, Su Liping   

  1. Department of Hematology, Shanxi Provincial Cancer Hospital, Third People′s Hospital of Shanxi Province, Taiyuan 030013, China
  • Online:2017-08-08 Published:2017-07-21
  • Contact: Su Liping, Email: sulp2005@sohu.com E-mail:sulp2005@sohu.com

Abstract: At present, immunotherapies for lymphoma are becoming gradually important. Chimeric antigen receptormodified T cells therapy, bispecific antibody and immunecheckpoint inhibitor are considered as breakthrough treatments, each has its own unique mechanism, and more advanced treatments will be developed based on them.

Key words: Lymphoma, Antibody, bispecific, Chimeric antigen receptor-modified T cells, Immunecheckpoint inhibitor